Clinical Trials at DKTK

© DKTK

© DKTK

The effectiveness and safety of new active substances, biomarkers, treatment and diagnostic approaches are first tested in a preclinical phase on cell cultures and animal models. Within the DKTK, special mouse and cell culture systems are being developed that produce results that can be transferred to the human immune system. The effectiveness, dosage and safety of the new treatment and diagnostic concepts are then checked in clinical trials lasting months or years. The research focus within the DKTK is on clinical phases I and II. Promising approaches are then developed further in the laboratory and optimised before going through further clinical control phases.

NOA-16 (PhaseI)

In this trial, physicians are testing the effectiveness of a vaccine against a mutation of the IDH-1 protein in patients with brain tumours (gliomas).

The trial is investigating how well the patient’s immune system responds to the peptide vaccine.

More information on NOA-16

N2M2 (Phase I and II)

In this register trial, molecular genetic analysis is carried out on tumour cells from patients with a particularly aggressive form of brain tumour (glioblastoma). Based on the molecular changes identified, clinical trials then develop targeted, personalised treatments.

More information on N2M2

INFORM (Phase I)

In this register trial, scientists hope to open up new treatment options for children with recurrent cancer and children in the advanced stages of cancer who have run out of conventional treatment approaches. The basis is the analysis of the entire tumour genome at the moment the cancer returns. From this, the researchers can discover which factors stimulate cancer growth and may be able to help the child with one of the new targeted drugs.

More information on INFORM

RAPS (Phase I and II)

This large-scale trial is designed to help improve colon cancer prevention for people in at-risk families in Germany. The trial participants are divided into risk groups so that experts can offer them individual advice and develop new prevention strategies.

More information on RAPS (in German only)

HNprädBio (Phase I and II)

The aim of this trial is to test certain biomarkers that can be used to predict how well radiochemotherapy is likely to work in patients with head and neck tumours.

More information on HNprädBio(in German only)

PSMA (Phase I and II)

This patient trial is investigating how reliably metastases can be identified in patients with prostate cancer using the non-invasive 68Ga-PSMA-11 diagnosis method.

MEMORI (Phase II)

Patients with a tumour of the oesophagus (adenocarcinoma) are often treated with chemotherapy or radiotherapy before an operation to reduce the size of the tumour. However this pre-op treatment is not successful in all patients. The trial is studying new biomarkers which can be used to divide patients into prognosis groups.

PORTAF (Phase II)

Radiotherapy is often used after an operation to reduce the risk of a recurrence. This trial is comparing the effectiveness of different radiotherapy methods for lung cancer.

More information on PORTAF

Oli-P (Phase II)

This trial is investigating the effectiveness of high-dose radiotherapy in patients with metastasizing prostate cancer.

More information on Oli-P

 

ReKo (Phase II)

Head and neck tumours are currently treated primarily with radiotherapy, chemotherapy and operative methods. This trial is studying the effectiveness and safety of high-dose proton therapy in patients with recurrent head and neck tumours.

Information on ReKo at NIH

AIO-TRK-0212

This trial is comparing the effectiveness and safety of various chemotherapy combinations in patients with lung cancer. Scientists are also using the trial material to research the molecular mechanisms that lead to therapy resistance in some lung cancer cases.

More information on AIO-TRK-0212 (inGerman only)

RELAZA2

Patients with recurrent acute myeloid leukaemia (AML) are being studied to see to what extent further development of the tumour can be delayed or prevented by the active cytostatic substance 5-azacytidine. The scientists also plan to use blood samples to identify new genetic markers that can be used to estimate the probability of recurrence in advance.

Coordinators
Karsten Spiekermann (Partner Site München)
Christian Thiede (Partner Site Dresden)

PETra

Radioactively marked amino acid 11C-methionine is often used to detect tumour cells during positron emission tomography (PET). This trial is checking how reliably the method can be used to predict the time and location of a potential recurrence in the case of malignant brain tumours.

More information on PETra

TRANSATRA

In this trial the efficacy of the drug ATRA is tested in combination with the LSD-1 inhibitor Tranylcypromin in patients with acute myeloid leukemia.